Rani Therapeutics (RANI) Stock
Biotech company developing swallowable capsules for injectable drugs. Here's the price, business snapshot, and what's worth knowing about Rani Therapeutics in October 2026.
Rani Therapeutics (RANI) is a small-cap, clinical-stage biotechnology company developing an oral delivery platform for large-molecule therapeutics. With a market capitalisation around $205m, the business is centred on its RaniPill approach — a swallowable capsule designed to deliver biologic drugs without injections. Investors should know this is an early-stage story: most value hinges on clinical readouts, regulatory progress and potential partnerships or licensing deals. Revenues are currently limited and the company may need additional funding, which can dilute shareholders. The share price can be volatile and outcomes are binary around trial and approval milestones. This summary is for general educational purposes only and not personal investment advice. Consider your risk tolerance, investment horizon and seek regulated financial advice if unsure. Past performance or the promise of technology does not guarantee future returns; values can rise and fall.
Rani Therapeutics (RANI) Stock Forecast
Analyst price target, next 12 months
$9.57
+1080.5% vs today's $0.81
Price range over the last 12 months
Close to its 12-month low
Analysts covering Rani Therapeutics have a consensus 12-month target of $9.57, above the current price of $0.81.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Rani Therapeutics stock, expecting its value to rise significantly.
Financial Health
Rani Therapeutics is generating modest revenue and cash flow, but its financial position shows room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Oral biologics platform
Rani’s RaniPill aims to transform how large-molecule drugs are delivered, potentially expanding patient access — though outcomes depend on clinical success.
Clinical catalysts ahead
Trial readouts and regulatory milestones can materially affect valuation; these binary events drive volatility and present both upside and downside risks.
Partnership potential
Licensing or collaborations with pharma firms could accelerate commercialisation, yet deals are uncertain and may take time to materialise.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
